Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients

Optimal care for breast cancer patients undergoing aromatase inhibitor (AI) treatment is ensured when estradiol (E(2)) levels are adequately suppressed. To assess treatment efficacy accurately, it is important to measure the serum E(2) levels using a well validated assay method with high sensitivity...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jaque, Jenny, Macdonald, Heather, Brueggmann, Doerthe, Patel, Sherfaraz K, Azen, Colleen, Clarke, Nigel, Stanczyk, Frank Z
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3599208/
https://ncbi.nlm.nih.gov/pubmed/23520572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-2-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars